XML 37 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Series A
Preferred Stock
Common Stock
Additional Paid-in- Capital
Reserves
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Total Mawson Stockholders’ Equity
Non- controlling interest
Common Shares
Share Subscription Receivable
Total
Balance at Dec. 31, 2020 $ 34,457,051 $ 652,949 $ (1,341,826) $ (26,159,539) $ 7,591,945 $ (27,066)   $ (16,690) $ 7,564,879
Balance (in Shares) at Dec. 31, 2020             7,539,275    
Exchange of stock and Reverse recapitalization of Wize Pharma Inc $ 461,324 (5,436,541) (4,975,217)   (4,975,217)
Exchange of stock and Reverse recapitalization of Wize Pharma Inc (in Shares) 178 46,132,357             (7,539,275)    
Issuance of common stock, net of offer costs, PIPE transaction $ 25,000 2,975,000 3,000,000   3,000,000
Issuance of common stock, net of offer costs, PIPE transaction (in Shares) 2,500,000                
Issuance of convertible notes, net of offer costs 20,301,427 20,301,427   20,301,427
Issuance of common stock, exercise of warrants $ 116 12,417,576 12,417,692   12,417,692
Issuance of common stock, exercise of warrants (in Shares) 41,000             30,613    
Fair value of IPR&D acquired, net of Business Combination transaction costs 24,765,831 24,765,831   24,765,831
Issuance of RSU’s and stock options $ 1,901 411,137 10,000,000 10,413,038   10,413,038
Issuance of RSU’s and stock options (in Shares) 190,098             (30,613)    
Fair value adjustment of LO2A intellectual property revenue sharing obligation 5,440,863 5,440,863   5,440,863
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio $ 50,558 50,558   50,558
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio (in Shares) 5,055,813                
Other           43,135 43,135       43,135
Net loss (44,803,128) (44,803,128)   (44,803,128)
Other comprehensive income (4,696,444) (4,696,444)   (4,696,444)
Non-controlling interest (65,802)   (65,802)
Balance at Jun. 30, 2021 $ 538,899 82,914,768 23,070,525 (6,038,270) (70,919,532) 29,549,700 (92,868)   (16,690) 29,456,832
Balance (in Shares) at Jun. 30, 2021 178 53,919,268                
Balance at Mar. 31, 2021 $ 486,440 82,914,768 17,534,625 (5,957,154) (64,722,747) 30,239,242 16,069   (16,690) 30,255,311
Balance (in Shares) at Mar. 31, 2021 178 48,673,357                
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio $ 50,558 50,558   50,558
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio (in Shares) 5,055,813                
Share based payments W Capital 5,535,900 5,535,900   5,535,900
Issuance of common stock at the price of $87.50  
Issuance of common stock at the price of $87.50 (in Shares)                 30,613    
Other           43,138 43,138       43,138
Share based payment - Issuance of BIA $ 1,901 1,901   1,901
Share based payment - Issuance of BIA (in Shares)   190,098             (30,613)    
Net loss (6,239,923) (6,239,923)   (6,239,923)
Other comprehensive income (81,116) (81,116)   (81,116)
Non-controlling interest (108,937)   (108,937)
Balance at Jun. 30, 2021 $ 538,899 82,914,768 23,070,525 (6,038,270) (70,919,532) 29,549,700 (92,868)   $ (16,690) 29,456,832
Balance (in Shares) at Jun. 30, 2021 178 53,919,268                
Balance at Dec. 31, 2021   $ 611,504 165,600,831 20,177,233 (521,094) (71,123,259) 114,745,215 (164,626)     114,580,589
Balance (in Shares) at Dec. 31, 2021   70,746,508                  
Issuance of common stock, stock based compensation   $ 20 134,879 408,584 543,483     543,483
Issuance of common stock, stock based compensation (in Shares)   18,787                  
Issuance of warrants   667,333 667,333     667,333
Issuance of RSU’s and stock options   $ 1,726 4,208,611 (4,148,724) 61,613     61,613
Issuance of RSU’s and stock options (in Shares)   1,726,000                  
Net loss   (13,453,059) (13,453,059) (522,648)     (13,975,707)
Other comprehensive income   (2,008,958) (2,008,958) 13,028     (1,995,930)
Non-controlling interest   (917,684) 1,623,458 705,774 534,019     1,239,793
Balance at Jun. 30, 2022   $ 613,250 169,026,637 17,104,426 (2,530,052) (82,952,860) 101,261,401 (140,227)     101,121,174
Balance (in Shares) at Jun. 30, 2022   72,491,295                  
Balance at Mar. 31, 2022   $ 612,344 167,664,681 18,447,842 62,214 (82,458,914) 104,328,167 (399,045)     103,929,122
Balance (in Shares) at Mar. 31, 2022   71,585,295                  
Issuance of common stock, stock based compensation   $ 5 27,145 408,584 435,734     435,734
Issuance of common stock, stock based compensation (in Shares)   5,000                  
Issuance of warrants   500,500 500,500     500,500
Issuance of RSU’s and stock options   $ 901 2,252,495 (2,252,500) 896     896
Issuance of RSU’s and stock options (in Shares)   901,000                  
Net loss   (2,117,403) (2,117,403) (288,229)     (2,405,632)
Other comprehensive income   (2,592,266) (2,592,266) 13,028     (2,579,238)
Non-controlling interest   (917,684) 1,623,457 705,773 534,019     1,239,792
Balance at Jun. 30, 2022   $ 613,250 $ 169,026,637 $ 17,104,426 $ (2,530,052) $ (82,952,860) $ 101,261,401 $ (140,227)     $ 101,121,174
Balance (in Shares) at Jun. 30, 2022   72,491,295